Statistics
MSI, infarct
SECONDARY, INFARCT
The primary aim was to assess group differences in cytokine levels between tocilizumab and placebo, in patients with STEMI treated by primary PCI. A mixed between-within subjects analysis of variance was performed to assess the impact of the intervention (between group—tocilizumab vs placebo) and the time interaction (within groups—multiple timepoints). Due to multiple comparisons, we applied Bonferroni correction (α=0.05/23 cytokines) resulting in a cut-off p value of 0.002 for postanalysis.The cytokines with a group×time interaction p<0.002 were analysed for between-group differences in changes from baseline using an independent sample t-test. Pearson correlation coefficient was calculated for the area under the curve (AUC) for the same cytokines against MSI (the primary endpoint in the main study) and infarct size, TnT, CRP (all secondary aims in the main study) and neutrophils. For both the temporal assessment of cytokines and for correlations with endpoints, we also performed sensitivity analysis according to symptom duration (≤3 or > 3 hours) as stratified in the main study. Apart from the initial between-within subjects analysis of variance, a two-sided p<0.05 was considered significant.Interleukin-9 and MIP-1β were normally distributed, otherwise all results were log-transformed to reach near normal distribution.IBM SPSS Statistics V.28.0.1.0 (142) was used for the analysis.